Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?

Roncato, Rossana; Angelini, Jacopo; Pani, Arianna; Talotta, Rossella

doi:10.1016/j.bbalip.2022.159140

Cited by 14 publications

(18 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the cases of HIV-1, HSV-1, and Newcastle disease virus, the major role in the fusogenic activity of viral peptides was attributed to cholesterol ( Martín et al, 2012 ; Apellániz et al, 2014 ; Vitiello et al, 2015 ). Recent data also indicate that CHOL-enriched membrane domains are of key importance for SARS-CoV-2 entry into cells ( Li et al, 2021 ; Alketbi et al, 2021 ; Sanders et al, 2021 ; Bakillah et al, 2022 ; Roncato et al, 2022 ). Moreover, viral fusion peptides, particularly that of HIV, preferentially target the L o /L α boundary regions ( Yang et al, 2015 ; Molotkovsky et al, 2018 ).…”

Section: Resultsmentioning

confidence: 99%

Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs

et al. 2023

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs

et al. 2023

View full text Add to dashboard Cite

“…Hypothesized downregulators of ACE2 receptors namely estradiol (3, Figure 3), retinoic acid (4, Figure 3), isotretinoin (5, Figure 3), and spironolactone (6, Figure 3) are also under consideration in line with this strategy (Figure 3). 109 ACE2 modulation by estrogens leading to decreased release of cytokines and inhibiting the activation of host immune response, thrombosis and fibrosis and in a way preventing the deterioration in the COVID-19 outcome has also come to light, making Raloxifene (7, Figure 3) (selective estrogen receptor modulator) an attractive agent for COVID-19 treatment. 110 Another approach necessitates reduced cell surface ACE2 caused by the impairment of ACE2 trafficking which can be brought about by a pharmacological compound, Berbamine (8, Figure 3).…”

Section: Lipid-inspired Therapeutics For Covid-19mentioning

confidence: 99%

“…Treatment of Caco-2 cells with Camostat mesylate ( 9 , Figure ), a TMPRSS2 inhibitor, has been shown to partially prevent SARS-CoV-2 infection, Figure . Apart from inhibiting viral entry into cultured lung cells, Camostat mesylate also prevents the propagation of the virus in human lung tissues as tested in ex vivo experiments. , On account of its role in viral and host membrane fusion, TMPRSS2 inhibitors such as bicalutamide ( 10 , Figure ), bromhexine ( 11 , Figure ), and nafamostat ( 12 , Figure ), are also being hypothesized to be able control SARS-CoV-2 infection …”

Section: Lipid-inspired Therapeutics For Covid-19mentioning

confidence: 99%

Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions

Dasgupta,

Gangai,

Narayan

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

The COVID-19 pandemic ignited research centered around the identification of robust biomarkers and therapeutic targets. SARS-CoV-2, the virus responsible, hijacks the metabolic machinery of the host cells. It relies on lipids and lipoproteins of host cells for entry, trafficking, immune evasion, viral replication, and exocytosis. The infection causes host cell lipid metabolic remodelling. Targeting lipid-based processes is thus a promising strategy for countering COVID-19. Here, we review the role of lipids in the different steps of the SARS-CoV-2 pathogenesis and identify lipid-centric targetable avenues. We discuss lipidome changes in infected patients and their relevance as potential clinical diagnostic or prognostic biomarkers. We summarize the emerging direct and indirect therapeutic approaches for targeting COVID-19 using lipid-inspired approaches. Given that viral protein-targeted therapies may become less effective due to mutations in emerging SARS-CoV-2 variants, lipid-inspired interventions may provide additional and perhaps better means of combating this and future pandemics.

show abstract

“…In both SARS-CoV-2 [ 37 ] and EBOV [ 41 , 42 ], the T cell Ig and mucin domain (TIM) family of proteins is shown to be involved in the above mentioned mechanism. Lipid raft domains rich in cholesterol and sphingolipids, on cellular membranes that play a significant role in viral trafficking and pathogenicity, are also studied in SARS-CoV-2 [ 43 ] and EBOV Virus [ 44 ].…”

Section: A Comparative Look At the Pathogenic Rna Viruses—sars-cov-2 ...mentioning

confidence: 99%

RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease

Dhanya¹,

Shailaja

Mary

et al. 2022

Pathogens

View full text Add to dashboard Cite

Pathogenic viruses with an RNA genome represent a challenge for global human health since they have the tremendous potential to develop into devastating pandemics/epidemics. The management of the recent COVID-19 pandemic was possible to a certain extent only because of the strong foundations laid by the research on previous viral outbreaks, especially Ebola Virus Disease (EVD). A clear understanding of the mechanisms of the host immune response generated upon viral infections is a prime requisite for the development of new therapeutic strategies. Hence, we present here a comparative study of alterations in immune response upon SARS-CoV-2 and Ebola virus infections that illustrate many common features. Vaccination and pregnancy are two important aspects that need to be studied from an immunological perspective. So, we summarize the outcomes and immune responses in vaccinated and pregnant individuals in the context of COVID-19 and EVD. Considering the significance of immunomodulatory approaches in combating both these diseases, we have also presented the state of the art of such therapeutics and prophylactics. Currently, several vaccines against these viruses have been approved or are under clinical trials in various parts of the world. Therefore, we also recapitulate the latest developments in these which would inspire researchers to look for possibilities of developing vaccines against many other RNA viruses. We hope that the similar aspects in COVID-19 and EVD open up new avenues for the development of pan-viral therapies.

show abstract

Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?

Cited by 14 publications

References 168 publications

Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs

Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs

Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions

RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease

Contact Info

Product

Resources

About